Clinical Trial Update: First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone [Phase 1]

View source ↗

Summary

Phase 1 trial update for M3258 (saracatinib-like investigational) in single agent and combination with dexamethasone in multiple myeloma; study terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• M3258 (M3258)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2023-03-24